ClinicalTrials.gov
public full text
Public Domain
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
The aim of the study is to evaluate the efficacy of sorafenib, compared to the best supportive care (BSC), in two cohorts of patients who presented with advanced hepatocellular carcinoma (HCC) based on etiology of hepatitis C virus.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)#842976
- Predictors of HCC in Post-HCV Cirrhotic Patients After SVR#916089
- A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib#1007286
- Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients#994395
- Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy#967194
Record · ID 1101487
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive